Discover how AI and machine learning are revolutionizing small molecule drug discovery—from generative models and molecular graphs to multi-objective optimization that designs novel, drug-like compounds in silico.
Learn how tirzepatide, a next‑generation “twincretin” peptide, combines dual GIP/GLP‑1 agonism, albumin binding, and DPP‑4 resistance to enable once‑weekly dosing, powerful glucose lowering, and surgery‑level weight loss in type 2 diabetes and obesity.
Discover how AI‑driven pharmacovigilance 2.0 transforms drug safety from passive, delayed reporting to real‑time, predictive risk intelligence by integrating spontaneous reports, EHRs, claims data, and patient voice for earlier, more precise signal detection.
Discover how Novartis’s investigational NMDA modulator MIJ821 offers rapid antidepressant effects for treatment‑resistant depression with fewer dissociative, cognitive, and cardiovascular side effects than ketamine and esketamine.
Discover how next-generation small molecule PROTACs work as “molecular assassins” by harnessing the ubiquitin–proteasome system to degrade disease-driving proteins, overcome drug resistance, and expand drug discovery beyond traditional inhibitors.
Discover how AI-powered pharmacovigilance is transforming drug safety from reactive reporting to proactive risk prediction using digital safety twins, real-world data, and real-time machine learning signal detection.
Discover why tirzepatide is more than “another GLP‑1.” Learn how its dual GIP/GLP‑1 agonism, advanced peptide engineering, and once‑weekly dosing deliver deeper glucose control, powerful weight loss, and broad metabolic benefits compared to traditional GLP‑1 drugs.
Learn how AI-powered pharmacovigilance uses machine learning, NLP, and advanced analytics to automate case intake, enhance signal detection, and deliver real-time drug safety intelligence across EHRs, social media, and more.
Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, is transforming type 2 diabetes and obesity treatment with powerful HbA1c reduction and weight loss results that rival bariatric surgery.
Learn what PROTACs (Proteolysis-Targeting Chimeras) are, how they hijack the ubiquitin–proteasome system to degrade disease-driving proteins, and why these small molecule degraders are game-changers for targeting undruggable cancer proteins and overcoming drug resistance.